• A Case of Diffuse Large B Cell Lymphoma With Rapidly Developing Abdominal Distension As the Only First Clinical Presentation
• A case of Richter transformation to diffuse large B-cell lymphoma with aberrant T-cell marker expression
• A nu mouse model of diffuse large B-cell lymphoma in constitutional Atm loss
• A Rare Case of Atrial Septal Mass Secondary to Lymphoma: Case Report and Review of Literature
• A systematic review and meta-analysis on utilizing anti-CD19 chimeric antigen receptor T-cell therapy as a second-line treatment for relapsed and refractory diffuse large B-cell lymphoma
• Application Effect of 18F-FDG PET/CT Technique in Diagnosis and Prognosis Evaluation of Lymphoma
• Assessing the impact of aprepitant on response to dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP)
• Association between skeletal muscle mass and treatment response in patients with diffuse large B-cell lymphoma
• Association of race/ethnicity and insurance with survival in patients with diffuse large B-cell lymphoma in a large real-world cohort
• B cells expressing mutated IGHV1-69-encoded antigen receptors related to virus neutralization show lymphoma-like transcriptomes in patients with chronic HCV infection
• Baseline (18)F-FDG PET/CT radiomics for prognosis prediction in diffuse large B cell lymphoma with extranodal involvement
• BCL6 confers resistance to HDAC inhibitors in DLBCL
• Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial
• Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial
• Central nervous system prophylaxis in large B-cell lymphoma: A British Society for Haematology Good Practice Paper
• Characterization of the genomic landscape of HIV-associated lymphoma reveals heterogeneity across histological subtypes
• Clinical and Biomarker Characteristic of Lymphoma Patients in Hasan Sadikin Lymphoma Registry
• Clinical characteristics and outcome of early-stage diffuse large B cell lymphoma of female genital track: A retrospective study of the Hellenic cooperative lymphoma group
• Clinical Impact of Microbiome Characteristics in Treatment-Naive Extranodal NK/T-Cell Lymphoma Patients
• Clinicopathologic Insights and Molecular Oncogenesis: Understanding Epstein-Barr Virus-Induced B-cell Lymphoproliferations
• Clinicopathological and Molecular Characteristics of Rare EBV-associated Diffuse Large B-cell Lymphoma With IRF4 Rearrangement
• Clinicopathological Profile of Primary Extra Nodal Lymphoma from a Tertiary Care Center in South India
• Comparison of Cox regression and generalized Cox regression models to machine learning in predicting survival of children with diffuse large B-cell lymphoma
• Comparison of R-CHOP-14 and R-mini-CHOP in older adults with diffuse large B-cell lymphoma-A retrospective multicenter cohort study
• Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma
• Complete detection of FR1 to FR3 primer-based PCR patterns of immunoglobulin heavy chain rearrangement in the BIOMED-2 protocol is associated with poor prognosis in patients with diffuse large B-cell lymphoma
• Contemporary Standard of Care Therapy for Richter's Transformation and Future Directions
• Correlation Between the Hepatitis C Virus NS3 Protein and CD30 Expression in Diffuse Large B-cell Lymphoma
• Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas
• Costs of care during chimeric antigen receptor T-cell therapy in relapsed/refractory B cell lymphomas
• Cutaneous Post-transplant Lymphoproliferative Disorder
• Cytokine release syndrome after chimeric antigen receptor T cell therapy in patients with diffuse large B-cell lymphoma: a systematic review
• DETECTION OF CIRCULATING TUMOR DNA FOR DISEASE MONITORING IN PATIENTS WITH PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA, LEG TYPE
• Diffuse large B-cell lymphoma in the C8 root mimicking a schwannoma: illustrative case
• Diffuse large B-cell lymphoma presenting with pulmonary artery compression symptoms, case reports
• Diffuse large B-cell lymphoma with multiple bone involvement as the initial symptom of frontal mass: a case report
• DNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphoma
• Enhanced prognostic evaluation of diffuse large B-cell lymphoma: A comprehensive surveillance study incorporating Epstein-Barr virus infection status and immunohistochemical markers
• Epidermodysplasia Verruciformis and Vδ2 γδ T-cell Expansion in STK4 Deficiency
• Erratum: An immunohistochemical study of diffuse large B-cell lymphoma with molecular subtyping based on Hans algorithm
• Evaluation of the effects of MCVAC conditioning regimen followed by autologous hematopoietic stem cell transplantation in patients with relapsed and refractory Hodgkin lymphoma: A single-institution retrospective study
• Expanded profiling of WD repeat domain 5 inhibitors reveals actionable strategies for the treatment of hematologic malignancies
• Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy
• Fluid Overload-Associated Large B-Cell Lymphoma with Light Chain Restriction Type Plasma Cell Infiltration: A Case Report
• Giant ovarian solid and cystic masses mixed with three types of tumors: A rare case report and literature review
• Harnessing Deep Learning for Accurate Pathological Assessment of Brain Tumor Cell Types
• Hematolymphoid neoplasm mimicking endodontic lesions: case series and review of the literature
• Hemophagocytic Lymphohistiocytosis in the Context of Hematological Malignancies and Solid Tumors
• HHV-8+ diffuse large B-cell lymphoma with EBV coinfection occurring posttransplant
• Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials-a LYSA and GLA/ DSHNHL collaboration
• Identify truly high-risk TP53-mutated diffuse large B cell lymphoma patients and explore the underlying biological mechanisms
• IgG4-related Disease Concomitant with Diffuse Large B-cell Lymphoma
• Improving accuracy of GPT-3/4 results on biomedical data using a retrieval-augmented language model
• Indolent T-cell lymphoma of the gastrointestinal tract with synchronous diffuse large B-cell lymphoma: report of a case
• Infections and their prognostic significance before diagnosis of chronic lymphocytic leukemia, non-Hodgkin lymphoma, or multiple myeloma
• International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline (18)F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation
• KMT2D mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-induced regulatory T cell trafficking via FBXW7-NOTCH-MYC/TGF-beta1 axis
• Lumbosacral epidural lymphoma: A case report and comprehensive review of literature
• Maxillary Diffuse Large B-Cell Lymphoma Enshrouded as Osteomyelitis: A Case Report
• MetaGate: Interactive analysis of high-dimensional cytometry data with metadata integration
• Multiple primary diffuse large B-cell lymphoma masquerading as meningioma
• Natural killer cell-associated prognosis model characterizes immune landscape and treatment efficacy of diffuse large B cell lymphoma
• Non-Hodgkin lymphoma incidence, mortality, and survival trends in Brunei Darussalam from 2011 to 2020
• Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma
• Pathological landscape of tumor flare reaction to epcoritamab treatment
• Phase IB Study of Oral Selinexor in Combination with Rituximab and Platinum Chemotherapy in Patients with Relapsed/Refractory B-Cell Lymphoma-Final Analysis
• Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol
• Predicting lymphoma prognosis using machine learning-based genes associated with lactylation
• Primary Bladder Lymphoma with Extravesical Extension: A Case Report and Literature Review on Prognosis and Clinical Characteristics
• Primary breast lymphoma: A rare case report
• Primary Cutaneous Spindle Cell B-Cell Follicle Center Lymphoma Presenting as Long-Standing Plaque of Cicatricial Alopecia: A Case Report With a Comprehensive Review of the Literature
• Primary hepatic diffuse large B- cell lymphoma mimicking cholangiocarcinoma
• Prognostic stratification in DLBCL patients with aberrant MYC gene
• Progress in deciphering the role of p53 in diffuse large B-cell lymphoma: mechanisms and therapeutic targets
• Prolonged Responses in Central Nervous System Relapsed Diffuse Large B-Cell Lymphoma After Chimeric Antigen Receptor T-Cell Therapy Using Targeted Treatments
• Pyoderma Gangrenosum in a 75-Year-Old Male With Follicular Diffuse Large B-cell Lymphoma
• Recombinant hirudin and PAR-1 regulate macrophage polarisation status in diffuse large B-cell lymphoma
• Recurrent Hypoglycemia in a 67-Year-Old Woman with CD5- Positive Diffuse Large B-Cell Lymphoma
• Repurposing NAMPT inhibitors for germinal center B-cell-like diffuse large B-cell lymphoma
• Rethinking the role of surgical resection in the management of primary pituitary lymphoma
• Rupatadine-inhibited OTUD3 promotes DLBCL progression and immune evasion through deubiquitinating MYL12A and PD-L1
• Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance
• Serial regression of primary gastric diffuse large B cell lymphoma after Helicobacter pylori eradication therapy: A case report
• Spleen tyrosine kinase (SYK): an emerging target for the assemblage of small molecule antitumor agents
• Synchronous Invasive Ductal Carcinoma of Breast and Diffuse Large B-cell Lymphoma: A Case Report
• Targeted multiplex validation of CSF proteomic biomarkers: implications for differentiation of PCNSL from tumor-free controls and other brain tumors
• Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study
• TCP1 expression alters the ferroptosis sensitivity of diffuse large B-cell lymphoma subtypes by stabilising ACSL4 and influences patient prognosis
• The current status and future trends of BTK inhibitor for diffuse large B cell lymphoma
• The Health Impacts of Better Access to Axicabtagene Ciloleucel: The Case of Spain
• The K9 lymphoma assay allows a genetic subgrouping of canine lymphomas with improved risk classification
• The role of autologous bone marrow transplantation in primary effusion lymphoma: a case report and literature review
• Transcriptional activation of SIRT5 by FOXA1 reprograms glycolysis to facilitate the malignant progression of diffuse large B-cell lymphoma
• Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation
• Transition From Epstein-Barr Virus (EBV)-Positive Rectal Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma in the Lung
• Tumor-informed ctDNA assessment as a valuable prognostic and predictive biomarker in diffuse large B-cell lymphoma
• Unusual Presentation of Non-Hodgkin Lymphoma of Two Cases: Case Report
• Using Cure Modelling for Cost Effectiveness in the NICE Technology Appraisal of Polatuzumab Vedotin in Combination for Untreated Diffuse Large B Cell Lymphoma: An External Assessment Group Perspective
• Vitreoretinal large B- cell lymphoma (VR- LBCL): Clinical and pathological features and treatment outcomes
• Volumetric and textural analysis of PET/CT in patients with diffuse large B-cell lymphoma highlights the importance of novel MTVrate feature